(NASDAQ: INVA) Innoviva's forecast annual revenue growth rate of 7.03% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Innoviva's revenue in 2025 is $388,521,000.On average, 6 Wall Street analysts forecast INVA's revenue for 2025 to be $30,369,697,603, with the lowest INVA revenue forecast at $29,053,014,421, and the highest INVA revenue forecast at $31,411,230,637. On average, 6 Wall Street analysts forecast INVA's revenue for 2026 to be $32,988,110,154, with the lowest INVA revenue forecast at $30,952,896,287, and the highest INVA revenue forecast at $34,560,503,528.
In 2027, INVA is forecast to generate $35,621,476,518 in revenue, with the lowest revenue forecast at $32,860,255,058 and the highest revenue forecast at $39,269,459,053.